Open Access Repository

Item Statistical Overview

All items > Item: Cost-effectiveness of Bevacizumab Biosimilar LY01008 combined with chemotherapy as first-line treatment for chinese patients with advanced or recurrent nonsquamous non-small cell lung cancer
Downloads
Activity Overview
0Downloads
13Hits
TOP